Pulmonary permeability assessed by fluorescent-labeled dextran instilled intranasally into XXXX with LPS-induced @entity647 .

@entity19 @entity2823 @entity647
BACKGROUND: Several different methods have been used to assess pulmonary permeability in response to @entity647 ( @entity647 ). However, these methods often involve complicated procedures and algorithms that are difficult to precisely control. The purpose of the current study is to establish a feasible method to evaluate alterations in lung permeability by instilling fluorescently labeled dextran ( @entity2823 -Dextran) intranasally. METHODS/PRINCIPAL FINDINGS: For the @entity19 model of direct @entity647 , lipopolysaccharide (LPS) was administered intranasally. @entity2823 -Dextran was instilled intranasally one hour before the @entity19 were euthanized. Plasma fluorescence intensities from the LPS group were significantly higher than in the control group. To determine the reliability and reproducibility of the procedure, we also measured the lung wet-to-dry weight ratio, the protein concentration of the bronchoalveolar lavage fluid, tight and adherens junction markers and pathological changes. Consistent results were observed when the LPS group was compared with the control group. Simultaneously, we found that the concentration of plasma @entity2823 -Dextran was LPS dose-dependent. The concentration of plasma @entity2823 -Dextran also increased with initial intranasal @entity2823 -Dextran doses. Furthermore, increased fluorescence intensity of plasma @entity2823 -Dextran was found in the intraperitoneally LPS-induced @entity647 model. CONCLUSION/SIGNIFICANCE: In conclusion, the measurement of @entity2823 -Dextran in plasma after intranasal instillation is a simple, reliable, and reproducible method to evaluate lung permeability alterations in vivo. The concentration of @entity2823 -Dextran in the plasma may be useful as a potential peripheral biomarker of @entity647 in experimental clinical studies.
